Aptose Biosciences Inc.
APTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | $0 | -$0 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $37 | $28 | $46 |
| G&A Expenses | $11 | $16 | $15 | $19 |
| SG&A Expenses | $11 | $16 | $15 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $52 | $43 | $65 |
| Operating Income | $0 | -$52 | -$43 | -$65 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | $1 | $0 |
| Pre-Tax Income | -$25 | -$51 | -$42 | -$65 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$51 | -$42 | -$65 |
| % Margin | – | – | – | – |
| EPS | -5.73 | -7.58 | -6.8 | -11.01 |
| % Growth | 24.4% | -11.5% | 38.2% | – |
| EPS Diluted | -18.94 | -27.08 | -22.12 | -34.56 |
| Weighted Avg Shares Out | 4 | 7 | 6 | 6 |
| Weighted Avg Shares Out Dil | 1 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$52 | -$42 | -$65 |
| % Margin | – | – | – | – |